Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

• Published in: Annals of oncology Vol. 28; no. 3; pp. 583 - 589
• Main Authors: Osorio, J.C., Ni, A., Chaft, J.E., Pollina, R., Kasler, M.K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J.D., Merghoub, T., Rudin, C.M., Fish, S., Hellmann, M.D.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2017; Oxford University Press
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - pathology; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions - pathology; Female; Humans; Hyperthyroidism - chemically induced; Hyperthyroidism - genetics; Hyperthyroidism - immunology; Hyperthyroidism - pathology; hypothyroidism; Male; Middle Aged; Neoplasm Staging; non-small cell lung cancer; Original; PD-1; pembrolizumab; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - immunology; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; T-Lymphocytes - pathology; thyroid dysfunction; Thyroid Gland - drug effects; Thyroid Gland - immunology; Thyroid Gland - pathology; non-small cell lung cancer; pembrolizumab; hypothyroidism; PD-1; thyroid dysfunction

Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is generally well tolerated although immune-related adverse events (irAEs) can occur. Autoimmune thyroid dysfunction is among the most common i...